# A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis

Study · id `cardio:ct-nct07521007` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07521007](<https://clinicaltrials.gov/study/NCT07521007>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07521007

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 456 participants.

## Technical summary

Registry record NCT07521007. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-31 (actual); primary completion 2027-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 456 participants (planned count; ClinicalTrials.gov record NCT07521007, source copy `cardio:ctgov-nct07521007-2026-11-05`, retrieved 2026-11-18)
- Started: 2026-07-31 (actual) (ClinicalTrials.gov record NCT07521007, source copy `cardio:ctgov-nct07521007-2026-11-05`, retrieved 2026-11-18)
- Primary completion: 2027-07-31 (anticipated) (ClinicalTrials.gov record NCT07521007, source copy `cardio:ctgov-nct07521007-2026-11-05`, retrieved 2026-11-18)
- Completion: 2029-03-31 (anticipated) (ClinicalTrials.gov record NCT07521007, source copy `cardio:ctgov-nct07521007-2026-11-05`, retrieved 2026-11-18)
- Countries: United States; Australia; Canada; China (ClinicalTrials.gov record NCT07521007, source copy `cardio:ctgov-nct07521007-2026-11-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07521007-2026-11-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
- Acronym: PURIFY-TIMI 81
- Condition: Atherosclerosis
- Condition: Coronary Artery Disease
- Intervention (Drug): YN001/Placebo 40mg
- Intervention (Drug): YN001/Placebo 20mg
- Intervention (Drug): YN001/Placebo 0mg
- Lead sponsor: Beijing Inno Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY
- Collaborator: The TIMI Study Group
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as a collaborator: The TIMI Study Group (`cardio:org-the-timi-study-group`)

## Provenance

Content hash: 42e390fed7cffcfc26ab98909037237ede5849180ee9008260994730aa195263
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
